Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Jingjing Li"'
Autor:
Chengren Zhang, Cong Cao, Lili Liu, Yaochun Lv, Jingjing Li, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang
Publikováno v:
Expert Review of Anticancer Therapy. 23:107-115
It remains controversial whether primary tumor resection (PTR) improves survival in patients with asymptomatic, unresectable metastatic colorectal cancer (mCRC). Therefore, we conducted a meta-analysis to assess the latest evidence on clinical outcom
Autor:
Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang
Publikováno v:
Expert Review of Anticancer Therapy. 22:1333-1347
It remains controversial which targeted monoclonal antibodies combined with chemotherapy can provide better efficacy in wild-type KRAS/RAS metastatic colorectal cancer (mCRC) patients. Therefore, we used this meta-analysis to assess the latest eviden
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Publikováno v:
Investigational New Drugs. 40:709-717
Small cell lung cancer (SCLC) accounts for nearly 10-15% of all lung cancer cases. Although many chemotherapy drugs, such as cisplatin and etoposide, were approved as primary therapy for SCLC patients, the prognosis is poor. In this study, we aimed t
Autor:
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo
Publikováno v:
Journal of Experimental & Clinical Cancer Research. 42
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to exp
Autor:
Jie Ji, Yan Li, Jiao Feng, Yingqun Zhou, Qiang Yu, Jianye Wu, Weiqi Dai, Liwei Wu, Yuanyuan Zheng, Chuanyong Guo, Jingjing Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-16 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies
Autor:
Yang Liu, Zheng Chen, Wu Xianrui, Zhi zhao Chen, Feng-Jie Tang, Jun lin Liao, Jianda Zhou, Ke Cao, Jingjing Li, Zi zi Chen, Xiang Chen
Publikováno v:
Journal of Cellular and Molecular Medicine
Cutaneous melanoma (CM) is an aggressive cancer; given that initial and specific signs are lacking, diagnosis is often late and the prognosis is poor. RNA modification has been widely studied in tumour progression. Nevertheless, little progress has b
Autor:
Tianjie Pu, Tzu Ping Lin, Allen C. Gao, Boyang Jason Wu, Jing Wei, Lijuan Yin, Jingjing Li, Peng Duan, Jing Wang
Publikováno v:
Cancer Res
Androgen receptor (AR) is the primary oncogenic driver of prostate cancer, including aggressive castration-resistant prostate cancer (CRPC). The molecular mechanisms controlling AR activation in general and AR reactivation in CRPC remain elusive. Her
Autor:
Jingjing Li, Feng Qiang
Publikováno v:
Cancer Management and Research
Feng Qiang, Jingjing Li Department of Gastroenterology, the First Peopleâs Hospital of Huzhou, Huzhou, 313000, Peopleâs Republic of ChinaCorrespondence: Jingjing LiDepartment of Gastroenterology, the First Peopleâs Hospital of Huzhou,
Autor:
Haodi Lu, Lufen Duan, Yanxia Yu, Jingjing Li, Lu Shi, Sudong Xue, Qian Zhang, Qin Zhou, Chenqi Zhu, Erning Shang, Xinxin Yan, Lian Tang
Publikováno v:
Journal of chemotherapy (Florence, Italy). 34(7)
In vancomycin treatment, the rates of correct blood sampling and initial trough concentrations within the target range are very low. Studies of interventions by clinical pharmacists based on population pharmacokinetics (PPK) models are limited. This